DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer
Sponsor: RemeGen Co., Ltd.
A PHASE2 clinical study on Breast Cancer, this trial is actively recruiting participants. The trial is conducted by RemeGen Co., Ltd. and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .